Revvity, Inc. (RVTY)
Market Cap | 11.16B |
Revenue (ttm) | 2.77B |
Net Income (ttm) | 286.61M |
Shares Out | 120.15M |
EPS (ttm) | 2.35 |
PE Ratio | 39.52 |
Forward PE | 18.30 |
Dividend | $0.28 (0.30%) |
Ex-Dividend Date | Jul 18, 2025 |
Volume | 705,296 |
Open | 93.25 |
Previous Close | 93.99 |
Day's Range | 92.77 - 94.09 |
52-Week Range | 89.36 - 129.50 |
Beta | 1.02 |
Analysts | Buy |
Price Target | 126.08 (+35.73%) |
Earnings Date | Apr 28, 2025 |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company’s Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for tes... [Read more]
Financial Performance
In 2024, Revvity's revenue was $2.76 billion, an increase of 0.16% compared to the previous year's $2.75 billion. Earnings were $270.39 million, a decrease of -60.99%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price forecast is $126.08, which is an increase of 35.73% from the latest price.
News

Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2...

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chie...

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.

Revvity beats quarterly estimates on steady demand for medical equipment
Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for d...

Revvity Announces Financial Results for the First Quarter of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as comp...

Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2...

Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation
BOULDER, Colo.--(BUSINESS WIRE)-- #NGS--Watchmaker Genomics, a leader in high-performance genomics solutions, today announced an important milestone in providing comprehensive and robust automated sol...

Revvity Fuels the Future of Cancer Science with New Research Solutions
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., is set to unveil the VivoJect™ Image-Guided Injection System as part of its distinguished cancer research and discovery portfolio at the AACR Annual Mee...

Revvity to Hold Earnings Call on Monday, April 28, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company w...

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One™, a unified software platform evolved ...

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™....

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.

PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry
SHELTON, Conn.--(BUSINESS WIRE)--PerkinElmer, a global leader in analytical solutions and specialized services for (bio)pharma, applied and food markets, today announced the acquisition of Project Far...

Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infectio...

Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rig...

Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Ch...

Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending
Medical equipment maker Revvity forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research.

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP...

Revvity Ignites Scientific Breakthroughs at SLAS2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows ...

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, ...

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 20...

Revvity Announces FDA Clearance for First Automated Free Testosterone Test
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN's automated chemiluminesce...

Revvity to Present at J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. Presiden...

Safe Biopharma: Revvity's Recurring Revenues And Diagnostics
Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company's recurring revenue base (80%) ...

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.